Interestingly, median OS and risk of AML did not differ significantly between MDS with mutated TP53 and MDS/AML with mutated TP53. Figure 1E, F presents the Kaplan–Meier curves for OS and AML development. This evidence concerns the gene TP53 and acute myeloid leukemia.